Stephenson Global Scholar Grants accelerate breakthrough research aimed at ending pancreatic cancer — Applications open now through February 25. LOS ANGELES–(BUSINESS WIRE)–The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) today announced the opening of applications for its 2026 Stephenson Global Scholar Grants, a global funding opportunity in partnership with City of Hope, one of the … [Read more…]

LEXINGTON, Ky.–(BUSINESS WIRE)–#Biomanufacturing—Demeetra AgBio, a genome engineering company enabling research and biomanufacturing through advanced gene-editing technologies and engineered CHO host cells, announced the completion and full integration of its acquisition of Hera BioLabs. The transaction, completed June 1, resulted in Demeetra now holding expanded rights to the hyperactive Super piggyBac® transposase platform and technologies, establishing … [Read more…]

China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline hydrochloride) for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. Sarecycline hydrochloride is an innovative tetracycline-derived oral antibiotic treatment – the first that was specifically developed for use in dermatology. Almirall has entered into a … [Read more…]

U.S. FDA Approves YUVEZZI™ as the only dual-agent, once daily presbyopia-correcting eye drop LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the successful close of its Series B preferred stock financing and … [Read more…]

YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is the only dual-agent presbyopia-correcting eye drop intentionally designed to deliver durability, tolerability, and safety YUVEZZI was studied in two pivotal Phase 3 trials enrolling more than 800 patients, including the world’s largest and longest safety study for presbyopia eye drops1,2 YUVEZZI achieves miosis from 30-minutes up … [Read more…]

LANSING, Mich.–(BUSINESS WIRE)–Neogen Corporation (NASDAQ: NEOG) is voluntarily recalling all lots within expiry of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution, for use in dogs, cats, and horses, to the veterinarian level. Neogen distributes this product, which is manufactured by a third-party supplier. This recall has been initiated due to microbial contamination in certain lots of … [Read more…]

FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 at the Cliff Lodge in Snowbird, UT. About Personalis, Inc. At Personalis, we are … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–#digitalhealth–Today, venture capital firm Caduceus Capital Partners and the Scottsdale Institute announced that they have entered a collaborative partnership to achieve their shared goal of accelerating the transformation of healthcare delivery through strategic innovation. Scottsdale Institute, a premier membership organization of health system leaders, works to leverage information technology, operating models, and strategy … [Read more…]

New mobile experience is part of Intelas’ TechCONNECT mobile experience, connecting technicians, clinical staff, and hospital leaders on a single platform, helping accelerate issue resolution and improve real-time visibility across medical equipment service MOORESVILLE, N.C.–(BUSINESS WIRE)–Intelas, Compass Healthcare’s signature Healthcare Technology Management (HTM) brand, has launched TeamCHAMPS, a new mobile experience designed to simplify medical … [Read more…]

New 375mg vial addresses critical dosing gap for adult and pediatric patients living with T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma CAMBRIDGE, Mass.–(BUSINESS WIRE)–Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved the company’s oncology drug, Nelarabine Injection, in a larger vial size, 375mg/75mL, … [Read more…]